Find a Provider

James A. Hoxie, MD

James A. Hoxie, MD Physician

Professor of Medicine

Dr. Hoxie is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bone Marrow Transplant and Stem Cell Transplant Program
  • Hematology-Oncology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Internal Medicine, 1979
  • Medical Oncology, 1981

Conditions & Treatments:

  • HIV

Clinical Interests

Hematologic malignancies
Allogeneic stem cell and bone marrow transplantation

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Brown University, Rhode Island Hospital
Fellowship: Hospital of the University of Pennsylvania


Ad Hoc Member, NIAID Board of Scientific Counselors (Reviewing Laboratory of Molecular Microbiology and Laboratory of Viral Diseases), National Ad Hoc Member, NIH NIAID Board of Scientific Counselors (Reviewing Laboratory of Immunoregulation), National Fellow, American Academy of Microbiology, 2009, National Member (Chair), External Scientific Advisory Board, Collaboration for AIDS Vaccine Discovery: Comprehensive Antibody – Vaccine Immune Monitoring Consortium, Duke University Medical Center; 2007-present, National Member (Chair), External Scientific Advisory Committee for NIH HIV-RAD (Shan Lu, PI). University of Massachusetts. 2010-present., National Member Board of Scientific Counselors for NIH Vaccine Research Center, National Member of External Scientific Advisory Committees of several NIH Centers for AIDS Research: UCSF, Johns Hopkins, University of Rochester, UCLA, Baylor & University of Texas at Houston), National Member, AIDS Basic Sciences Research Review Committee (NIAID), 1989-91., Member, American Society of Clinical Investigation, 1992, Member, Association of American Physicians, 2000, Member, External Scientific Advisory Committee for NIH HIV-RAD (John Moore, PI). Weill-Cornell Medical College 2010-present., National Member, External Scientific Advisory Committee for NIH HIV-RAD (Matthias Schnell, PI). Thomas Jefferson University. 2010-present., Local Member, External Scientific Advisory Committee for NIH HIV-RAD (Ruth Ruprecht, PI). Dana Farber Cancer Institute. 2005-present., National Member, External Scientific Review Board of the Research Center for AIDS and HIV Infection (RCAHI), New York Veteran's Administration Hospital, 1992-present., Member, NIH AIDS Program Advisory Committee, 1992-5., Member, NIH Study Section (National Heart, Lung, and Blood Institute) for Detection of Carrier States in the Acquired Immune Deficiency Syndrome, 1983., Member, NIH Study Section (NIAID), Studies of Pathogenesis of Lentiviruses, 1987., Member, NIH Study Section, AIDS- AARR1: Molecular biology (1998-present), Member, Organizing Committee for Conference on Retroviruses and Opportunistic Infections, International Phi Beta Kappa,


Dr. Hoxie is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Research Interests:

Research Interests
Viral and cellular aspects of HIV (human immunodeficiency virus) and SIV (simian immunodeficiency virus) entry into cells; HIV and SIV pathogenesis; mechanisms of viral resistance to the host immune response; neutralizing antibodies.

Key words: AIDS, CD4, chemokine receptors, HIV, SIV, envelope glycoproteins, viral entry, neutralization, vaccine.

Description of Research
Research in Dr. Hoxie's lab is focused on identifying viral and cellular determinants that are relevant to the ability of HIV and SIV to infect cells and to evade host immune responses. Three specific areas of work include:

1. Producing modified HIV envelope glycoproteins for vaccine studies. This work is directed towards deriving HIV envelope glycoproteins that can elicit broadly neutralizing antibodies. Current approaches are deriving viruses lacking structures that are believed to shield the envelope from humoral immune responses.

2. Studies of CD4-independent isolates of HIV. Dr. Hoxie has described CD4-independent isolates of HIV-1 and HIV-2 that can infect cells using chemokine receptors without CD4. His lab has shown that the genetic basis for this phenotype results from mutations that expose the chemokine receptor binding site on gp120. Efforts are in progress to identify the structural basis for this effect and to use CD4-independent envelope glycoproteins as HIV vaccine candidates.

3. The role of the HIV/SIV cytoplasmic tail in pathogenesis. Dr. Hoxie's group has identified endocytosis signals in the cytoplasmic tails of HIV, SIV and FIV Env proteins that reduce Env expression on the surface of infected cells. Dr. Hoxie has proposed that these signals could be relevant in pathogenesis by enabling virus-producing cells to survive host anti-viral immune responses. He has shown in an SIV model that viruses with mutations in this domain are markedly attenuated in vivo and controllable by host immune responses. Ongoing studies are addressing the mechanism for this attenuation, the components of the host immune response that are involved, and defects in viral assembly that are believed to underlie this effect.

Rotation Projects
-Structure function studies of envelope glycoproteins focusing on mechanisms of CD4 and chemokine receptor engagement.
M-odulation of Envelope glycoproteins for the design of immunogens that can elicit broadly neutralizing antibodies.
-The role of the HIV/SIV cytoplasmic tail in pathogenesis.
-Studies evaluating mechanisms of neutralization sensitivity and resistance to antibodies.

Lab personnel:
Research Specialists:
Beth Haggarty
Josephine Romano
Andrea Polachini-Oliveira Jordan
Adrienne Swanstrom
Kitu Kumar
Mike Hogan
Samra Zelman
Post Docs:
George Leslie

Selected Publications:

Nolan KM, Jordan AP, and Hoxie JA: Effects of partial deletions within the HIV-1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors J. Virology 82 (2): 664-73,2008.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie J: Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists J. Virology 81 (18): 9956-66,2007.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW: V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies PLoS Pathogens 3 (8): e117,2007.

Fernando K, Hu H, Ni H, Hoxie JA, Weissman D: Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses Blood 9 (6): 2538-44,2007.

Byland R, Vance PJ, Hoxie JA, Marsh M: A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein Mol. Biol Cell 18 (2): 414-25,2007.

Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, Watson SP, Hoxie JA, Baribaud F, Pohlmann S: DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets J. Virology 80 (18): 8951-60,2006.

Wei Q, Stallworth JW, Vance PJ, Hoxie JA, Fultz PN: Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells Clin. Vaccine Immunology 13 (7): 768-78,2006.

View all publications

Academic Contact Info

522G Johnson Pavilion
3610 Hamilton Walk

Philadelphia, PA 19104
Phone: (215) 898-0261
Fax: (215) 573-7356
Patient appointments: 800-789-PENN (7366)

Related Links